Abeona eligible for milestones and royalties after FAYUVI approval
Abeona says Ultragenyx received FDA approval for FAYUVI (UX111), originally developed by Abeona as ABO-102, making Abeona eligible for commercial milestones and royalties under its 2022 out-licensing deal.